- To evaluate in both randomized arms: very good partial response (VGPR) or better rate as defined by the International Myeloma Working Group (IMWG) criteria, complete response (CR) rate per IMWG criteria, minimal residual disease (MRD) negativity rate in patients with CR or VGPR, time to progression (TTP), PFS in MRD negative patients, duration of response (DOR), PFS on next line of therapy (PFS2), overall survival (OS), overall response rate (ORR) (including crossover arm) per IMWG criteria (including crossover arm), safety (including crossover arm), and to assess disease-specific and generic health-related quality of life (HRQL)